BioWorld Asia

June 6, 2007

Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion

Bavarian Nordic A/S could earn a total of $1.6 billion from its contract with the U.S. Department of Health and Human Services to supply a stockpile of next-generation safe smallpox vaccines. (BioWorld International) Read More

UK Ponders Plan Promoting Payment Upon Performance

Lost Copies Of Genes Dictate Risk Of Autoimmune Diseases

Soaring Interest In RNA Field Nets Exiqon $62.7 Million IPO

Evolutec Calling It Quits After Product Failure

Other News To Note

Pharmaxon Obtains Mimetic Peptide For Cell Mobility Drugs

Transgene In Line For €10M Milestone On CIN Compound

No Abstract Read More

Industry Rejoices at Fudged EU Advanced Therapies Agreement

ASCO Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...